Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.57 |
| ▸ | EGFR | P00533 | 8/20 | 0.56 |
| ▸ | GSK3B | P49841 | 5/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748498 | 0.85 | EGFR (0.63) | AURKAEGFRGSK3BKDR | |
| SCHEMBL4531678 | 0.79 | AURKA (0.71) | AURKAEGFR | |
| SCHEMBL2179113 | 0.78 | AURKA (0.56) | AURKAEGFRAURKB | |
| SCHEMBL4525188 | 0.78 | AURKA (0.56) | AURKAEGFR | |
| SCHEMBL3052791 | 0.78 | KDM4E (0.68) | EGFR | |
| SCHEMBL4525203 | 0.78 | AURKA (0.57) | AURKAEGFRGSK3BKDRAURKB | |
| SCHEMBL4527312 | 0.75 | AURKA (0.68) | AURKAEGFR | |
| SCHEMBL4535136 | 0.74 | AURKA (0.64) | AURKAEGFR | |
| SCHEMBL6750025 | 0.74 | AURKA (0.64) | AURKAEGFR | |
| SCHEMBL6750362 | 0.74 | KMT2A (0.70) | AURKAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966217-B1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-05-08 | — | — | EP | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| EP-2158206-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-03 | — | — | EP | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2008155016-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155016-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1966217-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | AURKA 2987/4885EGFR 4267/4885GSK3B 2588/4885 |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, PNPO, TPMT | AURKA 2909/4885EGFR 4423/4885GSK3B 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.